We have used a high responder rat model to examine the role that non-MHC antigens play in corneal graft rejection. Recipients were backcross animals derived from a cross between two inbred strains, which mimicked the human outbred population in that donor and recipient could be matched or mismatched for MHC antigens, while non-MHC mismatches were variable and unknown. All mismatched grafts and 87% of matched grafts were rejected (median survival 11 and 17 days respectively). Despite numerous studies since the early 1970S1-1O the precise value of major histocompatibility com plex (MHC) matching in corneal transplantation is still not fully established, even in high-risk cases, although for other organs such as kidney and heart, matching is clearly beneficial. Conflicting results, particularly with respect to class II (HLA-DR) matching, have undoubtedly stemmed from many differences in study design (e.g. prospective versus retrospective, whether or not high-risk cases have From:
been considered separately), differences in selection criteria and in treatment protocols. In general class I (HLA-A and -B) matching appears beneficial, although in the recent US Collaborative Corneal Transplantation Studies (CCTS), involving aggres sive immunosuppression, no benefit of HLA match ing was evident during the 2 year follow-up period (although ABO matching appeared advantageous). DR matching has been claimed to be both beneficial8 and detrimental. 1O There remain a number of questions to be answered. It is said that 70% of rejection episodes occur within the first year,9,11,12 but studies of graft outcome are frequently concluded after 1 or 2 years. The effect of matching on long-term survival has not been considered, although rejection can occur as long as 15 years after transplantation. 13 Matching in humans is performed against a background of variable non-MHC mismatches. These, or other unexplored factors such as infectious agents, might contribute significantly to human graft rejection, particularly late-onset rejection. If non-MHC anti gens are important, they may explain inconsistent results of matching studies and affect future matching practices. Moreover, heavy immunosuppression, as given in the CCTS, may induce serious ocular side effects. We therefore need to address the question of whether or not matching permits lower doses of immunosuppression to be given.
What can be learnt about matching from animal models? The rat is a useful experimental animal because corneal transplantation is both technically feasible and yields reproducible results, while inbred strains of defined MHC type are available. Thus, donor and recipient can be matched for background genes and the effect of isolated MHC class I or II disparities can be examined. Conversely, the effect of non-MHC disparities can be assessed with precision by matching donor and recipient across the entire Eye (1995) 9,208-214 © 1995 Royal College of Ophthalmologists MHC complex. In humans, this cannot be done because non-MHC mismatches are supplemented by those of the less polymorphic MHC loci -HLA-C, -DP and -DQ -which are not included in matching protocols.
Since the first successful transplantation model in the rat was reported in 1985, 14 antigens we have tried to mimic the human outbred situation more closely using a backcrossed hybrid model derived from two inbred strains?O DA X LEW(RT11) rats were backcrossed to LEW and the offspring received female DA strain corneal grafts. The DA and LEW strains differ for an entire MHC haplotype and at multiple non-MHC loci and represent a strongly rejecting strain combination. Use of backcross animals as recipients simulates the human situation better than wholly inbred or congenic models in that grafts can be either matched or mismatched for MHC against a background of non-MHC mismatches that, as with humans, are variable for each donor-recipient pair. Recipients (either RT1 a l l or RT1 11 l , identified by indirect haemagglutination assay20) were either MHC matched or mismatched with the donor, while non MHC disparity varied theoretically from 0 to 100%, averaging 50% ( Fig. 1) . A high-risk situation was provoked by leaving sutures in place. Grafts were examined daily for 3 days, then four times weekly for signs of rejection (opacity, oedema and vascularisa tion). If rejection had not occurred by day 50, examination was reduced to two to three times weekly until at least day 100. The day of rejection was defined as the day when central donor corneal opacity and oedema became moderate or severe. In a total of 77 such transplants performed without immunosuppressive therapy, matching was beneficial (p = 0.00002; Fig. 2 ) but there was a high incidence of rejection of matched grafts, 87% of which were ultimately rejected. The clinical signs of rejection were similar in matched and mismatched grafts ( sensitisation of the reCIpIent to corneal antigens would occur via the draining lymph nodes, as occurs with skin. Some animals in our backcross experi ments were sensitised with female DA skin grafts prior to corneal transplantation. Sensitisation sig nificantly reduced survival in matched as well as in mismatched groups,z° showing that the non-MHC antigens responsible for rejection are shared with skin. As in humans, the precise identity of non-MHC targets is unknown, with the possible exception of the H-Y (male) antigen, which is expressed on cornea and can induce an immune response?3 This antigen was not involved in our experiments since all donors were female. In rats, erythrocyte antigens do not appear to be involved in rejection,z4 at least in unsensitised animals, although some reports indicate that they are important in humans.9. 25 It should be noted that the recipients of MHC matched grafts were all heterozygous (RTI a!1 ) at MHC loci. This heterozygosity might enhance the immune response by increasing the repertoire of donor peptides capable of presentation to T cells by recipient antigen presenting cells and is analogous to the human situation in that most humans are heterozygous at MHC loci. We next addressed the question of whether MHC matching would reduce the requirement for immu nosuppression.
Systemic immunosuppressants, although not routinely given after corneal transplan tation, are sometimes necessary in high-risk cases and therefore both systemic cyclosporin and topical steroid were tested. As previously, (DA X LEW)FJ x LEW recipients were tissue-typed and divided into groups that were either MHC-matched or mis matched with the DA donor. Equal proportions of males and females were included in each group. From the day of corneal transplantation one of three immunosuppressive treatments was given: (1) cyclos porin, 10 mg/kg per day for 14 days, (2) cyclosporin, 10 mg/kg per day for 28 days, or (3) 15 /-11 0. 1 % dexamethasone, topically to the transplanted eye, twice daily for 14 days. Control rats received vehicle alone. A further group of control rats (7 male and 4 female) received autografts followed by steroid treatment as above. Grafts were examined and scored as previously for opacity, oedema and vessel ingress. One autograft receiving dexamethasone developed a persistent epithelial defect during steroid treatment, accompanied by vascularisation and opacity and was killed. The remainder experi enced transient oedema during the first week, then cleared and remained clear for the study period. As in our previous study, there was a high incidence of rejection of matched grafts. All three immunosup pressive regimes significantly delayed rejection in MHC-mismatched groups compared with controls (Fig. 5) . However, in matched groups, although immunosuppression caused a trend towards delayed rejection, this was not significant, although blood levels of cyclosporin reached therapeutic levels (data not shown). Thus, the immune response to matched grafts appears to be relatively resistant to immuno suppression. The data confirm that the benefits of matching are less obvious with immunosuppressive therapy. This is not so much a result of the overall suppression of rejection, but because the response to non-MHC mismatches is less easily suppressed.
The resistance appeared to be a general effect in that it occurred with both topical and systemic treatment and with both agents. The phenomenon has previously been noted by Pinto et al?6 with respect to cyclosporin and skin graft rejection. RTIA (class I) mismatches were more easily suppressed than RTIB (class II) or RTIAB (class I and II) mismatches, while survival of MHC-matched grafts was not prolonged.
Further evidence of such resistance comes from a large multicentre international study on kidney transplants in man. In this study the well-documen ted improvement in survival of first and second graft afforded by the addition of cyclosporin to treatment regimes in the 1980s was not evident in the subgroup of patients where the donor was an HLA-identical sibling, i.e. where rejection was attributable only to non-MHC mismatches.27 Moreover, analysis of renal allograft failure in the United Kingdom from 1978 to 1988 showed that the beneficial effect of cyclosporin therapy disappeared 1 year after transplantation, as did the major benefit of HLA matching?8 This would be explicable if immunosuppression-resistant non-MHC antigens contribute disproportionately to late rejection.
The reasons for such resistance to immunosup pression are not clear. It is possible that non-MHC antigens are presented to the immune system by a different mechanism that is relatively resistant to suppression, e.g. indirectly via recipient antigen presenting cells rather than directly by dendritic cells of the donor. This notion is supported by the At present there is no direct evidence in man that non-MHC antigens play a role in corneal graft rejection. However, careful clinical studies per formed through the Corneal Transplant Follow-up Study in a series of 547 HLA-A, -B and -DR typed corneal transplants show that the relative risk of rejection increases with increasing mismatch for HLA-A and -B, but that HLA-DR mismatching appears to have no detrimental effect. Furthermore, the data suggest that HLA-DR matching; is asso ciated with an increased risk of rejection ! (Fig. 6) . This observation can be explained in theory if HLA DR molecules play a central role in allogeneic peptide presentation, where the latter are derived from HLA-A, -B, non-HLA or viral genes -i.e. as is proposed above for the rat, any mismatched gene products will be more efficiently presented where donor and recipient are matched at this locus (Fig. 4) .
Careful multicentre matching studies and further animal investigations are required to elucidate these clinical and experimental findings. In particular we need to determine whether pep tides derived from non-MHC mismatches are more efficiently presented where donor and recipient are partially or wholly MHC-matched.
